Valisure is honored to collaborate with leading healthcare organizations including the American Hospital Association (AHA), American Medical Association (AMA), American Society of Health-System Pharmacists (ASHP), and the United States Pharmacopeia (USP)—all of which play critical roles in advancing the quality, accessibility, and safety of medications in the U.S. healthcare system.
Together, these organizations work to support clinical decision-making, patient communication, and the availability of high-quality pharmaceuticals, reinforcing the importance of transparency and accountability across the drug supply chain.
In July 2020, Valisure Co-Founder & President David Light participated in the Virtual Summit on Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security, hosted by the AHA, AMA, ASHP, and USP. The summit brought together national experts to address vulnerabilities in the U.S. pharmaceutical supply chain and explore policy and industry recommendations.
David Light presented on drug contamination issues, specifically focusing on the presence of probable human carcinogens NDMA and DMF in valsartan, a commonly used blood pressure medication. These contaminants were found in both generic products and the branded version made by Novartis, underscoring systemic challenges in global drug manufacturing oversight.
The summit, later summarized in a paper published in the American Journal of Health-System Pharmacy (November 2020), focused on:
These efforts reflect a growing consensus that medication quality is not only a clinical priority, but a matter of national security.
Valisure is honored to collaborate with leading healthcare organizations including the American Hospital Association (AHA), American Medical Association (AMA), American Society of Health-System Pharmacists (ASHP), and the United States Pharmacopeia (USP)—all of which play critical roles in advancing the quality, accessibility, and safety of medications in the U.S. healthcare system.
Together, these organizations work to support clinical decision-making, patient communication, and the availability of high-quality pharmaceuticals, reinforcing the importance of transparency and accountability across the drug supply chain.
In July 2020, Valisure Co-Founder & President David Light participated in the Virtual Summit on Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security, hosted by the AHA, AMA, ASHP, and USP. The summit brought together national experts to address vulnerabilities in the U.S. pharmaceutical supply chain and explore policy and industry recommendations.
David Light presented on drug contamination issues, specifically focusing on the presence of probable human carcinogens NDMA and DMF in valsartan, a commonly used blood pressure medication. These contaminants were found in both generic products and the branded version made by Novartis, underscoring systemic challenges in global drug manufacturing oversight.
The summit, later summarized in a paper published in the American Journal of Health-System Pharmacy (November 2020), focused on:
These efforts reflect a growing consensus that medication quality is not only a clinical priority, but a matter of national security.
Valisure is honored to collaborate with leading healthcare organizations including the American Hospital Association (AHA), American Medical Association (AMA), American Society of Health-System Pharmacists (ASHP), and the United States Pharmacopeia (USP)—all of which play critical roles in advancing the quality, accessibility, and safety of medications in the U.S. healthcare system.
Together, these organizations work to support clinical decision-making, patient communication, and the availability of high-quality pharmaceuticals, reinforcing the importance of transparency and accountability across the drug supply chain.
In July 2020, Valisure Co-Founder & President David Light participated in the Virtual Summit on Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security, hosted by the AHA, AMA, ASHP, and USP. The summit brought together national experts to address vulnerabilities in the U.S. pharmaceutical supply chain and explore policy and industry recommendations.
David Light presented on drug contamination issues, specifically focusing on the presence of probable human carcinogens NDMA and DMF in valsartan, a commonly used blood pressure medication. These contaminants were found in both generic products and the branded version made by Novartis, underscoring systemic challenges in global drug manufacturing oversight.
The summit, later summarized in a paper published in the American Journal of Health-System Pharmacy (November 2020), focused on:
These efforts reflect a growing consensus that medication quality is not only a clinical priority, but a matter of national security.
Valisure is honored to collaborate with leading healthcare organizations including the American Hospital Association (AHA), American Medical Association (AMA), American Society of Health-System Pharmacists (ASHP), and the United States Pharmacopeia (USP)—all of which play critical roles in advancing the quality, accessibility, and safety of medications in the U.S. healthcare system.
Together, these organizations work to support clinical decision-making, patient communication, and the availability of high-quality pharmaceuticals, reinforcing the importance of transparency and accountability across the drug supply chain.
In July 2020, Valisure Co-Founder & President David Light participated in the Virtual Summit on Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security, hosted by the AHA, AMA, ASHP, and USP. The summit brought together national experts to address vulnerabilities in the U.S. pharmaceutical supply chain and explore policy and industry recommendations.
David Light presented on drug contamination issues, specifically focusing on the presence of probable human carcinogens NDMA and DMF in valsartan, a commonly used blood pressure medication. These contaminants were found in both generic products and the branded version made by Novartis, underscoring systemic challenges in global drug manufacturing oversight.
The summit, later summarized in a paper published in the American Journal of Health-System Pharmacy (November 2020), focused on:
These efforts reflect a growing consensus that medication quality is not only a clinical priority, but a matter of national security.